Frederick G. Vogt, Ph.D., J.D., is currently serving as the Interim Chief Executive Officer and President, as well as the General Counsel at Iovance Biotherapeutics, Inc. Dr. Vogt brings a unique blend of scientific and legal expertise to his role, having earned a Ph.D. in biochemistry from the University of California, San Francisco, and a J.D. from the University of California, Berkeley School of Law. His career spans both the biotechnology and legal sectors, making him a valuable asset to Iovance Biotherapeutics as the company advances its mission to develop innovative cancer immunotherapies. Before joining Iovance Biotherapeutics, Dr. Vogt held various leadership positions in the biotechnology industry, where he was instrumental in guiding companies through complex regulatory landscapes and facilitating the development of groundbreaking therapies. His strategic vision and deep understanding of both scientific and legal principles have been pivotal in driving the company's growth and success. As General Counsel, he has played a crucial role in navigating the intricate legal challenges associated with the development and commercialization of novel cancer treatments. In his current role as Interim CEO and President, Dr. Vogt is responsible for overseeing the overall strategic direction and operational execution at Iovance Biotherapeutics. His leadership has been vital in advancing the company's pipeline of tumor-infiltrating lymphocyte (TIL) therapies, which hold significant promise for patients with advanced cancers. Under his guidance, Iovance Biotherapeutics continues to strengthen its position as a leader in the field of immuno-oncology, with a focus on delivering life-changing treatments to those in need.